GlassScriptPhysician profile
Abhishek Kumar
NPI 1639443823
$73,928.08
in general payments reported to CMS, 2019-2025
27 companies · $27K in 2025
The $27K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $150 · 2021: $1,231 · 2022: $4,882 · 2023: $33K · 2024: $6,254 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $50K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,000 · Travel and Lodging: $5,453 · Food and Beverage: $3,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $49,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,000.00 |
| Travel and Lodging | $5,452.76 |
| Food and Beverage | $3,882.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $71,118.79 | 2021-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Pulmonx Corporation | $1,233.00 | 2022 | |
| Glaxosmithkline, LLC. | $230.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $202.05 | 2019-2023 | Tezspire |
| United Therapeutics Corporation | $139.06 | 2024 | Tyvaso |
| Penumbra, INC. | $137.00 | 2024 | Indigo System |
| Olympus America INC. | $91.71 | 2025 | |
| Grifols USA, LLC | $88.49 | 2019 | |
| Merck Sharp & Dohme LLC | $71.83 | 2019 | |
| Genentech USA, INC. | $70.16 | 2019-2020 | |
| Mylan Specialty L.P. | $65.47 | 2019 | |
| Gyrus Acmi, INC. | $59.58 | 2025 | Spiration Valve System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.52 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $48.35 | 2019 | |
| Kls-Martin L.P. | $48.24 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $40.93 | 2019 | |
| Philips North America LLC | $35.05 | 2019 | |
| Amgen INC. | $30.15 | 2025 | Tezspire |
| Circassia INC. | $27.00 | 2019 | |
| Shire North American Group INC | $24.84 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.13 | 2020 | |
| La Jolla Pharmaceutical Company | $17.74 | 2019 | |
| Medtronic, INC. | $16.80 | 2021 | |
| Advanced Respiratory, INC | $14.98 | 2020 | |
| Collegium Pharmaceutical, INC. | $14.89 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.08 | 2019 | |
| Veran Medical Technologies, INC. | $10.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhishek Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.